Safety and Efficacy of CPX-351 in Younger Patients < 60 Years Old with Secondary Acute Myeloid Leukemia: An Updated Analysis

被引：4

作者：

Przespolewski, Amanda ^{[1
]}

Goldberg, Aaron D. ^{[2
]}

Talati, Chetasi ^{[3
]}

Fazal, Salman ^{[4
]}

Vachhani, Pankit ^{[5
]}

Sanikommu, Srinivasa Reddy R. ^{[6
]}

Thota, Swapna ^{[7
]}

Waksal, Julian ^{[8
]}

Ball, Brian ^{[8
,9
]}

Famulare, Christopher ^{[10
]}

Stahl, Maximilian ^{[11
]}

Mckinnell, Zoe ^{[9
]}

Baron, Jeffrey ^{[12
]}

Griffiths, Elizabeth A. ^{[13
,14
]}

Thompson, James E. ^{[15
]}

Sweet, Kendra

Wang, Eunice S. ^{[1
]}

机构：

[1] Roswell Pk Comprehens Canc Ctr, Dept Med, Leukemia Serv, Buffalo, NY USA

[2] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, New York, NY USA

[3] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA

[4] Allegheny Hlth Network Canc Inst, Pittsburgh, PA USA

[5] Univ Alabama Birmingham, ONeal Comprehens Canc Ctr, Birmingham, AL USA

[6] Levine Canc Inst, Dept Hematol Oncol & Blood Disorders, Atrium Hlth, Charlotte, NC USA

[7] Univ Tennessee, St Jude Res Hosp, Hlth Sci Ctr, Memphis, TN USA

[8] Mem Sloan Kettering Canc Ctr, New York, NY USA

[9] City Hope Natl Med Ctr, Duarte, CA USA

[10] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, New York, NY USA

[11] Roswell Pk Comprehens Canc Ctr, Dept Pharm, Buffalo, NY USA

[12] Roswell Pk Comprehens Canc Ctr, Div Hematol, Dept Internal Med, Buffalo, NY USA

[13] Roswell Pk Comprehens Canc Ctr, Dept Med, Leukemia Serv, Buffalo, NY USA

[14] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA

[15] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-153791

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1264

引用

页数：5

共 50 条

[1] Safety and efficacy of CPX-351 in younger patients < 60 years old with secondary acute myeloid leukemia:An updated analysis
Przespolewski, Amanda Cecile
Talati, Chetasi
Fazal, Salman
Vachhani, Pankit
Sanikommu, Srinivasa
Thota, Swapna
Baron, Jeffrey
Griffiths, Elizabeth A.
Thompson, James E.
Sweet, Kendra Lynn
Wang, Eunice S.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[2] Safety and efficacy of CPX-351 in younger patients (<60 years old) with secondary acute myeloid leukemia
Przespolewski, Amanda
Goldberg, Aaron D.
Talati, Chetasi
Fazal, Salman
Vachhani, Pankit
Sanikommu, Srinivasa R.
Thota, Swapna
Waksal, Julian
Ball, Brian
Famulare, Christopher
Stahl, Maximilian
Baron, Jeffrey
Griffiths, Elizabeth A.
Thompson, James E.
Sweet, Kendra
Wang, Eunice S.
[J]. BLOOD, 2023, 141 (12) : 1489 - 1493
[3] Safety and Efficacy of Liposomal Cytarabine/Daunorubicin (CPX-351) in Younger Patients < 60 Years Old with Secondary Acute Myeloid Leukemia
Przespolewski, Amanda
Talati, Chetasi
Vachhani, Pankit
Sanikommu, Srinivasa Reddy
Thota, Swapna
Baron, Jeffrey
Griffiths, Elizabeth A.
Thompson, James E.
Sweet, Kendra L.
Wang, Eunice S.
[J]. BLOOD, 2018, 132
[4] A phase II study of CPX-351 in younger patients < 60 years old with secondary acute myeloid leukemia: Trial in progress.
Swaminathan, Mahesh
Fazal, Salman
Griffiths, Elizabeth A.
Thompson, James E.
Sung, Pamela Jeannette
Green, Steven Daniel
Li, Emily
Said, Meriem
Belko, Krista
Mattice, Emmalyn
Attwood, Kristopher
Wang, Eunice S.
Przespolewski, Amanda
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[5] Efficacy and Safety Profile of CPX-351 in Secondary Acute Myeloid Leukemia (sAML): A Systematic Review
Ibrahim, Ahmed
Yousaf, Muhammad Abdullah
Ikram, Mariam
Khalid, Huma
Anum
Safdar, Omar A.
Anwer, Zain
Faraz, Fatima
Rehman, Mohammad
Saad, Muhammad
[J]. BLOOD, 2023, 142
[6] CPX-351: changing the landscape of treatment for patients with secondary acute myeloid leukemia
Talati, Chetasi
Lancet, Jeffrey E.
[J]. FUTURE ONCOLOGY, 2018, 14 (12) : 1147 - 1154
[7] CPX-351 As Induction Chemotherapy Yields Similar Responses and Survival Outcomes in Younger Patients (<60 Years Old) Compared to Older Patients (≥60 Years Old) with Acute Myeloid Leukemia
Lee, Dasom
Asghari, Hannah H.
Deutsch, Yehuda E.
Chan, Onyee
Padron, Eric
Kuykendall, Andrew T.
List, Alan F.
Komrokji, Rami S.
Fernandez, Hugo F.
Lancet, Jeffrey E.
Sallman, David A.
Sweet, Kendra L.
Talati, Chetasi
[J]. BLOOD, 2019, 134
[8] CPX-351 Yields Similar Response and Survival Outcome in Younger and Older Patients With Secondary Acute Myeloid Leukemia
Lee, Dasom
Jain, Akriti G.
Deutsch, Yehuda
Eatrides, Jennifer
Chan, Onyee
Padron, Eric
Kuykendall, Andrew
Komrokji, Rami
Lancet, Jeffrey
Sallman, David
Talati, Chetasi
Sweet, Kendra
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (10): : 774 - 779
[9] CPX-351 in acute myeloid leukemia: can a new formulation maximize the efficacy of old compounds?
Brunetti, Claudia
Anelli, Luisa
Zagaria, Antonella
Specchia, Giorgina
Albano, Francesco
[J]. EXPERT REVIEW OF HEMATOLOGY, 2017, 10 (10) : 853 - 862
[10] CPX-351 for the Treatment of High-Risk Patients with Acute Myeloid Leukemia
Assi, Rita
Kantarjian, Hagop M.
Verstovsek, Srdan
Garcia-Manero, Guillermo
Konopleva, Marina
Ravandi, Farhad
DiNardo, Courtney D.
Kadia, Tapan M.
Daver, Naval
Jabbour, Elias J.
Gborogen, Rosilyn A.
Chamoun, Kamal
Wierda, William G.
Borthakur, Gautam
Cortes, Jorge E.
[J]. BLOOD, 2016, 128 (22)

← 1 2 3 4 5 →